ANTIBODIES TARGETING CDH19 FOR MELANOMA

ANTI-HSP70 ANTIBODIES AND THERAPEUTIC USES THEREOF

METHODS AND COMPOSITIONS FOR DOSING OF ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR T CELLS

COMBINED USE OF MULTIKINASE INHIBITOR

BISPECIFIC BINDING PROTEINS AND USES THEREOF

BISPECIFIC ANTIBODIES AND USES THEREOF

Humanized and Affinity-Matured Anti-CEACAM1 Antibodies

Immunoconjugates

BISPECIFIC ANTIBODIES AGAINST HER2

CELL INJURY INDUCING THERAPEUTIC DRUG FOR USE IN CANCER THERAPY

ANTI-CD70 ANTIBODIES, CONJUGATES THEREOF AND METHODS OF USING THE SAME

HIGH-EFFICIENCY, CONDITIONALLY-ACTIVATED ANTIBODY DISCOVERY AND MASKED ANTIBODIES

STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF

ANTI-TIGIT ANTIBODIES

Fusion Protein Construct

HIGH AFFINITY B7-H6 ANTIBODIES AND ANTIBODY FRAGMENTS

ANTIBODY TARGETING CD3, MULTISPECIFIC ANTIBODY, AND USES THEREOF

ANTI-PD1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS

PROTEINACEOUS COMPOUND FOR GENERATING SPECIFIC CYTOTOXIC T-CELL EFFECT

BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS

ANTI-CD38 BINDING MOLECULES AND USES THEREOF

ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES

ANTIBODIES AGAINST G-CSFR AND USES THEREOF

BISPECIFIC ANTI-VEGF AND ANTI-TRKB BINDING MOLECULES FOR THE TREATMENT OF EYE DISEASES

Anti-CD112R Compositions and Methods

MULTI-SPECIFIC T CELL ENGAGERS COMPRISING LRRC15 ANTIGEN-BINDING DOMAIN

CONSTITUTIVELY ACTIVE CHIMERIC CYTOKINE RECEPTORS

Antigen-Presenting Synthetic Surfaces, Covalently Functionalized Surfaces, Activated T Cells, and Uses Thereof

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

TRISPECIFIC ANTIBODY TARGETING CD79b, CD20, AND CD3

BISPECIFIC PD-L1x4-1BB ANTIBODIES AND METHODS OF USE THEREOF

ANTI-TNFR2 SINGLE DOMAIN ANTIBODY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

ANTIBODIES AGAINST EGFR AND THEIR USES

ANTI-B7H6 SCFV ANTIBODY, ITS CODING GENES AND THE APPLICATION THEREOF

ANTIBODY-CYTOKINE FUSION PROTEINS AND APPLICATIONS THEREOF

HUMANIZED MUC1 ANTIBODY AND ANTIBODY DRUG CONJUGATE

ANTI-CD33 ANTIBODIES AND USES THEREOF

USE OF SEMAPHORIN-4D ANTIBODIES IN COMBINATION WITH AN IMMUNE MODULATING THERAPY TO INHIBIT TUMOR GROWTH AND METASTASIS

DNA-CONTAINING POLYNUCLEOTIDES AND GUIDES FOR CRISPR TYPE V SYSTEMS, AND METHODS OF MAKING AND USING THE SAME

ADENOVIRUS ARMED WITH BISPECIFIC T CELL ACTIVATOR

MULTIFUNCTIONAL IMMUNE CELL THERAPIES

CHIMERIC ANTIGEN RECEPTORS AGAINST AXL OR ROR2 AND METHODS OF USE THEREOF

Identification of CLEC-1 Ligand and Uses Thereof

BISPECIFIC IGG ANTIBODIES AS T CELL ENGAGERS

CELLS EXPRESSING AN ANTI-MESOTHELIN CAR

ANTIBODY VARIABLE DOMAINS TARGETING THE NKG2D RECEPTOR

Bispecific Antibody against TIGIT and PD-L1, and Pharmaceutical Composition Thereof and Use Thereof

ALPHA AND GAMMA-D POLYGLUTAMATED ANTIFOLATES AND USES THEREOF

ANTI-CANCER PEPTIDE

HUMAN MESOTHELIN CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF

Methods of using anti-SP17 immunotherapeutics

Combination Therapies with Anti-CD38 Antibodies

BISPECIFIC ANTIBODY BINDING TO BCMA AND CD3, AND PREPARATION METHOD THEREFOR AND USE THEREOF

SIGLEC-6 ANTIBODIES, DERIVATIVE COMPOUNDS AND RELATED USES

CANCER SPECIFIC PLECTIN-1 SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF

VEGF-BINDING PROTEIN AND USE THEREOF

CHIMERIC ANTIGEN RECEPTORS

METHODS OF TREATING AGING-RELATED DISORDERS

Compositions and methods for targeted immunomodulatory antibodies and fusion proteins

ANTIBODIES COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE

MULTISPECIFIC ANTIBODIES BINDING TO CD20, NKP46, CD16 AND CONJUGATED TO IL-2

Camelid/Llama Nanobodies to Target WNT16B as a Chemotherapy Option for Cancer Treatment

ANTI-VEGF A AND VEGF C BISPECIFIC ANTIBODIES AND USE THEREOF

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

TREATMENT OF PERIPHERAL T CELL LYMPHOMA

MHC-INDEPENDENT TCRs AND METHODS OF MAKING AND USING SAME

COMPOSITIONS AND METHODS FOR MODULATING DELTA GAMMA CHAIN MEDIATED IMMUNITY

HUMANIZED ANTIBODIES AGAINST NECTIN-2 AND DRUG CONJUGATES THEREOF

SINGLE-DOMAIN 4-1BB ANTIBODIES

BCMA CHIMERIC ANTIGEN RECEPTORS

HETERODIMERIC ANTIBODIES THAT BIND PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND CD3

MONOCLONAL ANTIBODY TARGETING TIGIT

NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES

HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE

BISPECIFIC IMMUNE CELL ENGAGERS TARGETING HIV AND METHODS OF USE THEREOF

MacrophageexpressingChimeric Antigen Receptor for Binding FAP antigen and its construction method and uses thereof

CAR T CELLS GENERATED BY EFFECTOR PROTEINS AND METHODS RELATED THERETO

COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS

MULTISPECIFIC ANTIBODIES AND USES THEREOF

CD33 x Vd2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER

HUMANIZED ANTIBODIES AGAINST NECTIN-2 AND DRUG CONJUGATES THEREOF

ANTI-FOLATE RECEPTOR ANTIBODIES, COMPOSITIONS COMPRISING ANTI-FOLATE RECEPTOR ANTIBODIES AND METHODS OF MAKING AND USING ANTI-FOLATE RECEPTOR ANTIBODIES

STABILIZED TCR CONSTRUCTS AND METHODS OF USE

CONVERSION-RESISTANT / CONDITION-RESISTANT TREGS AND CAR TREGS, METHODS OF MAKING AND METHODS OF USING

COMPOSITIONS AND METHODS FOR THE DEPLETION OF CELLS

METHODS FOR MAKING AND USING THERAPEUTIC CELLS

DYNAMIC I/O VIRTUALIZATION SYSTEM HAVING GUEST MEMORY MANAGEMENT FOR MAPPING VIRTUAL ADDRESSES USING VIRTUALIZATION APPLICATION PROGRAMMING INTERFACE (API) IN GUEST KERNAL

BACTERIAL DELIVERY OF ANTIBODIES, ANTIBODY DERIVATIVES, AND POLYPEPTIDES TO EUKARYOTIC CELLS

MULTISPECIFIC ANTIBODIES AND USES THEREOF

SELECTIVE IMMUNODEPLETION OF ENDOGENOUS STEM CELL NICHE FOR ENGRAFTMENT

OPTIMIZED MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS

CLAUDIN 4 AND CLAUDIN 9 ANTIBODIES AND METHODS OF TREATING CANCER

ANTIBODY CONSTRUCTS FOR MSLN AND CD3

Anti-PfRH5 Antibodies and Antigen-Binding Fragments Thereof

ANTI-PERIOSTIN HUMANIZED MONOCLONAL ANTIBODY, AND PREPARATION METHOD THEREFOR AND USE THEREOF

ANTI-CD30 ANTIBODY AND CHIMERIC ANTIGEN RECEPTOR COMPRISING THEREOF

ANTIGEN-BINDING MOLECULE

MULTISPECIFIC PROTEINS BINDING TO NKP46, A CYTOKINE RECEPTOR, A TUMOUR ANTIGEN AND CD16A

ANTIBODIES AND METHODS FOR THE DIAGNOSIS, PREVENTION, AND TREATMENT OF EPSTEIN BARR VIRUS INFECTION

POLYGLUTAMATED ANTIFOLATES AND USES THEREOF

METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS

ANTI-VARIABLE MUC1* ANTIBODIES AND USES THEREOF

METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS

Anti-Jagged1 Antibodies and Methods of Use

ANTIBODIES BINDING TO HLA-A2/MAGE-A4

HUMANIZED AND AFFINITY MATURED ANTIBODIES TO FcRH5 AND METHODS OF USE

BISPECIFIC BINDING PROTEINS THAT BIND CD137 AND A TUMOR ASSOCIATED ANTIGEN

GENETICALLY ENGINEERED CELLS AND USES THEREOF

METHODS FOR THE TREATMENT OF ANAPLASTIC LARGE CELL LYMPHOMA

CHIMERIC ANTIGEN RECEPTOR AND CAR-T CELLS THAT BIND BCMA

ANTIBODIES AGAINST CLEAVED CDCP1 AND USES THEREOF

Multivalent and Multispecific DR5-Binding Fusion Proteins

UNIVERSAL CAR-T CELL TARGETING IL13RALPHA2, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

ANTI-NKp30 ANTIBODIES AND METHODS OF USE

T CELL PRODUCT AND USE THEREOF

CAR-EXPRESSING IMMUNE CELLS THAT SPECIFICALLY TARGET MESOTHELIN AND USES THEREOF

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING CD300C EXPRESSION INHIBITOR OR ACTIVITY INHIBITOR

Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors

ANTIBODIES AGAINST GPC3 AND USES THEREOF

ANTI-BCMA ANTIBODIES AND TREATMENT METHODS

ANTI-FOLR1 IMMUNOCONJUGATE REGIMENS

IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF

GRP78-BINDING ANTIBODIES AND USE THEREOF IN DETECTING OR NEUTRALIZING GRP78

GROWTH FACTOR ANTAGONISTS FOR ORGAN TRANSPLANT ALLOIMMUNITY AND ARTERIOSCLEROSIS

CHIMERIC ENGULFMENT RECEPTOR MOLECULES

SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS

ANTIBODIES AGAINST THE ECTODOMAIN OF ERBB3 AND USES THEREOF

HUMANIZED ANTIBODIES THAT BIND LGR5

Therapeutic Anti-CD9 Antibody

COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD117+ CELLS

USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENT

MULTISPECIFIC ANTIBODIES AND USES THEREOF

PROTEINS BINDING NKG2D, CD16 AND BAFF-R

ANTIBODY

TREATMENT OF FIBROSIS

METHOD FOR MODIFYING CELL

MASKED CHIMERIC ANTIGEN RECEPTOR SPECIFIC TO TYROSINE-PROTEIN KINASE LIKE 7 (PTK7) AND IMMUNE CELLS EXPRESSING SUCH

METHODS FOR TREATING MULTIPLE MYELOMA

METHODS FOR THE TREATMENT OF GPP

Inhibitors of complement factor H

Combination Therapy of Immunotoxin and Checkpoint Inhibitor

BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT

COMPOSITIONS AND METHODS FOR BCMA MODIFICATION

Compositions and Methods for Targeting Cancer Stem Cells

POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING GLYPICAN-3 AND T CELL RECEPTOR

Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs

CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS

ANTIBODIES AND MOLECULES THAT IMMUNOSPECIFICALLY BIND TO BTN1A1 AND THE THERAPEUTIC USES THEREOF

CONSTRUCTS HAVING A SIRP-ALPHA DOMAIN OR VARIANT THEREOF

ANTIBODY AGAINST GLYPICAN-3 AND APPLICATION THEREOF

Glycan-Interacting Compounds and Methods of Use

ENHANCED CHIMERIC ANTIGEN RECEPTORS AND USE THEREOF

ANTIBODIES TO CD40

NOVEL MULTI-SPECIFIC MOLECULES

COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER

METHODS OF USING CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN AND USES THEREOF

B CELL MATURATION ANTIGEN BINDING PROTEINS

COMPOSITIONS COMPRISING A T CELL REDIRECTION THERAPEUTIC AND A VLA-4 ADHESION PATHWAY INHIBITOR

A33 ANTIBODY COMPOSITIONS AND METHODS OF USING THE SAME IN RADIOIMMUNOTHERAPY

CD3-EXPRESSING NATURAL KILLER CELLS WITH ENHANCED FUNCTION FOR ADOPTIVE IMMUNOTHERAPY

METHOD FOR PRODUCING DIRECTLY REPROGRAMMED NATURAL KILLER CELLS AND USES THEREOF

HER2 SINGLE DOMAIN ANTIBODIES VARIANTS AND CARS THEREOF

VARIANTS OF CD38 ANTIBODY AND USES THEREOF

ANTI-PD-L1 ANTIBODY AND USE THEREOF

NOVEL DARPIN BASED CD33 ENGAGERS

METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES

IMMUNE CELLS HAVING CO-EXPRESSED SHRNAS AND LOGIC GATE SYSTEMS

ANTI-CD25 ANTIBODY AGENTS

BISPECIFIC TETRAVALENT ANTIBODY TARGETING EGFR AND HER3

HUMANIZED ANTI-CLEC-1A ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF AND MIMETICS THEREOF

HUMAN ANTI-SEMAPHORIN 4D ANTIBODY

ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE

IMPROVED ADOPTIVE CELL TRANSFER THERAPY FOR CANCER

CHIMERIC ANTIGEN RECEPTOR

ANTI-STEAP1 ANTIGEN-BINDING PROTEIN

TUMOR-ASSOCIATED ANTIGENS AND CD3-BINDING PROTEINS, RELATED COMPOSITIONS, AND METHODS

ANTIGEN BINDING MOLECULES WITH INCREASED FC RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION

BISPECIFIC ANTIBODY AND USE THEREOF

TRUNCATED TACI POLYPEPTIDE AND FUSION PROTEIN AND USE THEREOF

COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS

RECOMBINANT PROTEINACEOUS BINDING MOLECULES

CYTOTOXICITY-INDUCING THERAPEUTIC AGENT

BCMA Monoclonal Antibody-Drug Conjugate

HUMAN MESOTHELIN CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF

HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR

Method and Compositions for Inducing Differentiation of Myeloid Derived Suppressor Cell to Treat Cancer and Infectious Diseases

CEACAM5-dependent 4-1BB-agonistic bispecific antibodies

BISPECIFIC FUSION PROTEIN

ANTIGEN-BINDING POLYPEPTIDE BINDING TO CD47, AND USE THEREOF

ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS

CHIMERIC ANTIGEN RECEPTORS TARGETING G-PROTEIN COUPLED RECEPTOR AND USES THEREOF

NUCLEIC ACID ENCODING GENETICALLY ENGINEERED GROWTH FACTOR VARIANTS

MESOTHELIN ISOFORM BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS CONTAINING THE SAME AND USES THEREOF

CLAUDIN18.2 CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF

ARMED NK CELLS FOR UNIVERSAL CELL THERAPY

BIO PROTAC PROTEIN HAVING INTRACELLULAR DELIVERY FUNCTION, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

ANTI-PDL1 ANTIBODIES AND USES THEREOF

Antibody specifically binding to ICAM-1 and use thereof

TREATMENT OF EOSINOPHIL OR MAST CELL RELATED DISORDERS

VHH-BASED NKP30 BINDERS

ANTIBODIES SPECIFIC TO NELL2 AND METHODS OF USE

TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS

CHIMERIC POLYPEPTIDE ASSEMBLY AND METHODS OF MAKING AND USING THE SAME

CELLS EXPRESSING VISTA ANTIGEN-BINDING MOLECULES

A PHAGE-DISPLAYED SINGLE-CHAIN VARIABLE FRAGMENT LIBRARY FOR SELECTING ANTIBODY FRAGMENTS SPECIFIC TO MESOTHELIN

COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITOR

Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus

CELLS EXPRESSING HER3 ANTIGEN-BINDING MOLECULES

ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES

CANCER METASTASIS INHIBITOR

ANTI-TIM3 ANTIBODIES AND METHODS OF USE

HUMAN NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 SPIKE S2 DOMAIN AND USES THEREOF

ANTI-CD47 ANTIBODY FOR COMBINED TREATMENT OF BLOOD TUMOR

CYTOTOXICITY-INDUCING THERAPEUTIC AGENT

DIAGNOSTIC INDICATORS AND THERAPEUTIC TARGETS OF RHEUMATOID ARTHRITIS

GPRC5D CHIMERIC ANTIGEN RECEPTORS AND CELLS EXPRESSING THE SAME

COMBINATION THERAPY OF PD-1-TARGETED IL-2 VARIANT IMMUNOCONJUGATE AND ANTI-TYRP1/ANTI-CD3 BISPECIFIC ANTIBODIES

CLEC12AXCD3 BISPECIFIC ANTIBODIES AND METHODS FOR THE TREATMENT OF DISEASE

COMPOUNDS AND METHODS FOR TREATING PAIN

TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR

NKG2C+ T CELLS AND METHODS OF USE THEREOF

Anti-CD45 antibodies and conjugates thereof

PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION

CD33 SPECIFIC CHIMERIC ANTIGEN RECEPTORS

Antigen-Binding Domain

BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS

MULTISPECIFIC ANTIBODIES

GROUP B ADENOVIRUS ENCODING AN ANTI-TCR-COMPLEX ANTIBODY OR FRAGMENT

CELL-PENETRATING ANTI-DNA ANTIBODIES AND USES THEREOF INHIBIT DNA REPAIR

TARGETING TUMOR CELLS WITH CHEMOTHERAPEUTIC AGENTS CONJUGATED TO ANTI-MATRIPTASE ANTIBODIES BY IN VIVO CLEAVABLE LINKING MOIETIES

TARGETED REDUCTION OF ACTIVATED IMMUNE CELLS

CYTOTOXICITY-INDUCING THERAPEUTIC AGENT

SIRP α, SIRP β 1, and SIRP γ antibodies and uses thereof

ANTIBODY CONJUGATE COMPRISING ANTI-P-CADHERIN ANTIBODY AND USES THEREOF

TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR

IMMUNOTOXINS WITH ALBUMIN BINDING DOMAIN

ANTIBODIES TARGETING FLT3 AND USE THEREOF

Agents for Treatment of Claudin Expressing Cancer Diseases

NOVEL ENGINEERED T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME

ANTI-UNC5C ANTIBODIES

Chimeric Antigen Receptors with MAGE-A4 Specificity and Uses Thereof

METHODS FOR EXPANSION OR DEPLETION OF T-REGULATORY CELLS

INHIBITOR OF SUV39H1 HISTONE METHYLTRANSFERASE FOR USE IN CANCER COMBINATION THERAPY

HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF

COMPOSITIONS AND METHODS FOR THE DEPLETION OF CELLS

PD-L1-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS

ANTI-AXL ANTIBODIES, ANTIBODY FRAGMENTS AND THEIR IMMUNOCONJUGATES AND USES THEREOF

MONOCLONAL ANTIBODIES AND CONJUGATES AGAINST PROSTAGLANDIN F2 RECEPTOR INHIBITOR AND USES THEREOF

Anti-IL-23 Antibodies

THERAPEUTIC CD99 ANTIBODIES

CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS

mRNA display antibody library and methods

ANTI-PD-1 ANTIBODIES AND USES THEREOF

CD33 SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY

MULTl-CHAIN POLYPEPTIDE-CONTAINING TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS

POLYPEPTIDES TARGETING DR4 AND/OR DR5 AND RELATED COMPOSITIONS AND METHODS

Adenovirus armed with bispecific T cell activator

FUSION PROTEINS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS

Antibody Constructs for CLDN18.2 and CD3

Single chain binding molecules comprising N-terminal ABP

ANTIGEN-BINDING MOLECULES THAT BIND CD38 AND/OR CD28, AND USES THEREOF

ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF

BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN6 OR CLAUDIN18.2 AND CD3 FOR TREATMENT OF CLAUDIN EXPRESSING CANCER DISEASES

BI-SPECIFIC TARGETED CHIMERIC ANTIGEN RECEPTOR T CELLS

MULTIFUNCTIONAL IMMUNE CELL THERAPIES

ANTIBODIES, ACTIVATABLE ANTIBODIES, BISPECIFIC ANTIBODIES, AND BISPECIFIC ACTIVATABLE ANTIBODIES AND METHODS OF USE THEREOF

MATRIX METALLOPROTEINASE SUBSTRATES AND OTHER CLEAVABLE MOIETIES AND METHODS OF USE THEREOF

ANTI-VISTA CONSTRUCTS AND USES THEREOF

ANTI-TIGIT ANTIBODIES AND METHODS OF USE THEREOF

ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF

Immunotoxins with albumin binding domain

COMBINATION THERAPIES WITH ANTI CD40 ANTIBODIES

ANTIBODIES TARGETING FLT3 AND USE THEREOF

METHODS AND MATERIALS FOR TREATING CLONAL T CELL EXPANSIONS

PREPARATION OF SIGLEC-15 BINDING PROTEIN AND USE THEREOF

METHODS AND COMPOSITIONS RELATED TO A TISSUE FACTOR-TARGETING IGG3 IMMUNOCONJUGATES

NUCLEIC ACID SEQUENCING USING AFFINITY REAGENTS

CONDITIONALLY ACTIVE ANTI-EPCAM ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND USES THEREOF

TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS

CLDN18.2/CD3 BISPECIFIC ANTIBODIES FOR THE THERAPY OF CLDN18.2-EXPRESSING SOLID TUMORS

MONOCLONAL ANTIBODIES AGAINST CLAUDIN-18 FOR TREATMENT OF CANCER

CHIMERIC ANTIGEN AND T CELL RECEPTORS AND METHODS OF USE

HUMAN CD3 BINDING ANTIBODY

Compositions and Methods for Treating Cancer with Anti-CD22 Immunotherapy

MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND METHODS OF USING THE SAME

ANTI-MET ANTIBODIES AND USES THEREOF

ANTI-FGFR3 ANTIBODY AND USE THEREOF

MESOTHELIN BINDING PROTEINS

METHODS AND COMPOSITIONS FOR ENHANCING THE POTENCY OF SUPERANTIGEN MEDIATED CANCER IMMUNOTHERAPY

ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME

ANTI-SIGLEC-15 ANTIBODY AND APPLICATION THEREOF IN PREPARING DRUG

ENGINEERED CYCLOTIDES WITH POTENT BROAD ANTIMICROBIAL ACTIVITY

ANTI-B-CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTORS WITH HUMAN DOMAINS

COMPOSITIONS AND METHODS FOR DETECTING AND TREATING ESOPHAGEAL CANCER

MATRIX METALLOPROTEINASE SUBSTRATES AND OTHER CLEAVABLE MOIETIES AND METHODS OF USE THEREOF

Anti-Chemokin Like Receptor 1 Humanized Antibodies and Their Therapeutic Applications

MONOCLONAL ANTIBODY AGAINST HUMAN MAC-1 AND USES THEREOF

BISPECIFIC ANTI-CD3 ANTIBODIES, BISPECIFIC ACTIVATABLE ANTI-CD3 ANTIBODIES, AND METHODS OF USING THE SAME

SINGLE CHAIN VARIABLE FRAGMENT CD3 BINDING PROTEINS

HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODIES TO CD47